In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Selected Start-Ups (06/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: BioProtocol Inc.'s web site,, will offer life scientists free access to high quality protocols to guide their research. Locus Discovery Inc. has a computational approach for designing small molecule therapeutics that can act as inhibitors or activators of protein activity. Morphotek Inc. is developing an in vivo technology that can alter the genome of microbe, plant, and mammal host cells to produce organisms with commercially viable output traits. NitroOSystems Inc. hopes that its tolerance-free nitrate therapy will become the standard of care for the treatment of angina, congestive heart failure, hypertension, and other cardiovascular disorders. Repair Inc. is developing therapeutics for cardiovascular disease based on its proprietary drug delivery and angiogenesis technologies. Unipharm Technologies Limited claims that its approach to drug delivery will render existing quick dissolve oral dosage forms unnecessary and aid drugs that have negative esophgeal or gastric mucosal effects.

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts